clinical trial · NCT06844357
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Zhejiang Raygene Pharmaceuticals Co., Ltd·phase3·recruiting·n = 300
HCCtirapazamineTransarterial Embolization (TAE)TACE
brief summary
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.
started
Mar 27, 2025
primary completion
Apr 1, 2029
completion
Apr 1, 2029
last updated
Apr 6, 2025
official title
A Multi-center, Randomized, Controlled, Open-label Phase II/III Clinical Trial to Investigate Whether Transarterial Tirapazamine Injection Followed by Transarterial Embolization (TATE) is Superior to Traditional Transarterial Chemoembolization (TACE) in Patients With Intermediate-Stage Hepatocellular Carcinoma (HCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol